The first ready-to-eat weight loss pill is here! Lilly's Foundayo has received FDA approval, no fasting required, no waiting needed

Eli Lilly’s GLP-1 oral weight-loss drug, Foundayo, received FDA approval for market launch in the United States, marking the beginning of a new phase in the global weight-loss drug market competition for oral medications.

On April 1, Eli Lilly stated that this once-daily weight-loss medication called Foundayo is the only GLP-1 weight-loss pill that can be taken at any time during the day without restrictions on eating or drinking.

In-stock supplies will be shipped via Lilly’s direct sales platform, LillyDirect; subsequently, it will gradually be introduced into major U.S. pharmacies and telehealth platforms. Patients with insurance can pay only $25 per month using Lilly coupons, while self-paying patients will pay between $149 and $349 depending on dosage.

According to Bloomberg’s compilation of Wall Street analysts’ forecasts, sales of Foundayo are expected to reach $18 billion by 2030. On Wednesday, Eli Lilly’s stock price intraday surged up to 6%, while competitor Novo Nordisk’s ADR declined by over 2%.

（On Wednesday, Eli Lilly shares closed nearly 4% higher, while Novo Nordisk’s ADR rose only about 1%）

Fast approval—only about three months behind Novo Nordisk

Foundayo’s approval process took less than four months, thanks to the FDA’s fast-track review pathway established specifically for innovative drugs of national priority.

Since Eli Lilly submitted its application this year, Foundayo’s market entry was only about three months later than Novo Nordisk’s oral Wegovy, and the competitive landscape between the two has quickly taken shape.

Eli Lilly acquired the global rights to Foundayo’s active ingredient, orforglipron, in 2018 from Chugai Pharmaceutical in Japan, with an upfront payment of $50 million.

Currently, Eli Lilly has already prepared a large inventory to ensure rapid distribution, and expects regulatory approvals in over 40 countries within the next year.

Since 2020, Eli Lilly has invested over $55 billion in manufacturing, including new facilities and capacity expansions.

Slightly lower efficacy, but convenience and accessibility provide a differentiating advantage

Efficacy remains Eli Lilly’s core challenge.

In independent clinical trials, the oral Wegovy helped patients lose an average of about 13.6% of body weight over 64 weeks, while Foundayo’s weight loss ranged from approximately 11% to 12.4% (variations due to different statistical methods).

In comparison, Eli Lilly’s injectable Zepbound achieved weight loss exceeding 20%.

Nevertheless, most physicians consider a weight loss of around 11% to be clinically meaningful.

Foundayo’s key advantage lies in its ease of use: patients can take it at any time during the day without fasting or water restrictions, whereas Wegovy oral must be taken on an empty stomach in the morning with a small amount of water, and patients must wait 30 minutes before eating.

Eli Lilly CEO Dave Ricks stated in a media interview that injections have not become the primary barrier to patient acceptance as initially expected, but he still regards Foundayo as an important option for patients who prefer oral medication or seek lower prices.

Global expansion potential—possibly the biggest highlight for Foundayo

Foundayo and Zepbound differ fundamentally in product attributes.

Foundayo is a small-molecule compound, whereas Zepbound and Wegovy are peptide-based drugs; the latter involves more complex manufacturing processes and stricter cold chain logistics. This characteristic gives Foundayo a unique advantage in rapidly expanding globally.

Ricks said:

This enables large-scale production, allowing us to launch simultaneously worldwide at the initial market entry. As long as we obtain regulatory approvals in various regions, we already have the capacity to supply oral GLP-1 inhibitors globally.

Currently, Wegovy oral is only available in the U.S. and has not yet been introduced in other markets.

Ricks also noted that as a small-molecule drug, Foundayo naturally avoids the competitive pressure from generic versions of Wegovy launched by competitors in certain markets, including India, because the barriers to producing generics of peptide drugs are inherently higher.

Pricing is a critical variable; Medicare coverage could unlock additional market demand

Regarding pricing, both drugs have the same starting dose price—$149 per month for self-pay patients—based on an agreement previously reached between Eli Lilly, Novo Nordisk, and the Trump administration.

Starting this summer, Medicare-covered elderly patients will be able to access Foundayo and other GLP-1 weight-loss drugs for $50 per month as part of this agreement. Ricks expects this program will generate “quite strong” demand, and these expectations are already incorporated into Eli Lilly’s full-year financial guidance.

Nidhi Kansal, an obesity specialist at Northwestern University’s Feinberg School of Medicine, emphasized that price is currently the main factor influencing clinical decisions. She said:

Unfortunately, in the decision-making process for doctors and patients choosing a medication, price is the key driver. Because all these drugs are excellent, and we now have many options, but ultimately, it remains an economic decision.

BMO Capital Markets analyst Evan David Seigerman believes that the lower price threshold combined with the appeal of the oral format is likely to attract potential patients who have been hesitant, further expanding the overall weight-loss drug market.

Foundayo’s approval is a key signal for Eli Lilly’s stock stabilization

Analysts generally agree that whether Foundayo can successfully increase volume is crucial for Eli Lilly’s stock performance.

So far this year, Eli Lilly’s stock has fallen about 14% from its peak. Previously, its market capitalization briefly surpassed $1 trillion, making it the first U.S. healthcare company to cross that milestone.

Cantor Fitzgerald analyst Carter Gould said that sales data lag behind actual demand, so the market will closely monitor prescription volumes to assess how quickly Foundayo is gaining market share. He said:

If prescription trends remain favorable and continue to grow, I expect investors will tolerate fluctuations in quarterly performance.

Meanwhile, the key clinical data readout for Eli Lilly’s more potent obesity injection, retatrutide, is also an important catalyst this year. Eli Lilly has disclosed some late-stage clinical data, but the core trial results specifically evaluating weight-loss efficacy have not yet been released.

Analysts believe that once the retatrutide data meets expectations, Eli Lilly will establish a comprehensive product matrix covering oral and injectable obesity treatments across different efficacy tiers.

FactSet data shows that analysts project sales by 2030 for Foundayo, Zepbound, and Mounjaro (approved in the U.S. for diabetes and in other markets for both diabetes and obesity) to be approximately $14.8 billion, $24.7 billion, and $44.9 billion, respectively.

Risk Disclosure and Disclaimer

        The market involves risks; investments should be made cautiously. This article does not constitute personal investment advice and does not consider individual users’ specific investment goals, financial situations, or needs. Users should evaluate whether any opinions, viewpoints, or conclusions herein are suitable for their circumstances. Investment decisions are at your own risk; you bear all responsibilities.